Microgravity leaves anticoagulation for venous thromboembolism without direct human evidence
Human exposure to microgravity may alter venous return, vascular tone, coagulation pathways, and platelet behavior in ways that plausibly raise venous thromboembolism risk. Yet a new hybrid systematic and narrative review found no eligible studies that directly tested anticoagulants for prevention or treatment of VTE in astronauts or in microgravity analogs. The evidence gap is stark: a field with clear physiologic concern has no direct clinical trial data to guide drug choice, dosing, monitoring, or safety in space.
The review searched 13 biomedical and aerospace databases, including MEDLINE, Embase, Scopus, Web of Science, the Cochrane Library, CINAHL, NASA and ESA repositories, ClinicalTrials.gov, and several space medicine archives. After screening across those sources, no study met the predefined PICOS criteria. In practical terms, there is no direct human evidence for how standard anticoagulant strategies behave when gravity-dependent hemodynamics are fundamentally altered.
Venous stasis and coagulation shifts create a plausible thrombotic pathway
The absence of trial data does not mean the biological concern is theoretical. Microgravity changes the distribution of blood and fluid, reduces the gravitational pull that normally assists venous return, and may contribute to venous stasis in the lower extremities and central venous system. Stasis is one leg of Virchow’s triad, and it matters because sluggish flow gives clotting factors more time to interact with the vessel wall and each other.
The synthesis pulled together physiologic and ground-based analog findings showing endothelial dysfunction, increased fibrinogen synthesis, altered platelet function, and a hypercoagulable state. Those changes point in the same direction even when they arise through different experimental models: the circulation in microgravity may become more thrombosis-prone through a combination of reduced shear stress, vascular remodeling, and shifts in coagulation biology. In a setting where plasma volume may redistribute and the endothelium loses some of the mechanical cues it normally receives on Earth, clotting behavior can become harder to predict.
A single sentence captures the central problem: there is no direct anticoagulation evidence where the physiology is least familiar.
Rare events in space do not eliminate concern for mission-critical decisions
VTE appears rare in spaceflight, and that low observed frequency likely reflects the small number of people exposed, the intensive screening used before missions, and the health profile of astronauts. Low event rates, however, do not settle the question of risk. Rare does not mean irrelevant when an untreated clot could compromise both mission performance and patient safety far from definitive care.
Space medicine faces a difficult therapeutic mismatch. Standard anticoagulation protocols on Earth rely on predictable pharmacokinetics, stable access to laboratory monitoring when needed, and the ability to respond quickly to bleeding. None of those assumptions can be carried uncritically into microgravity. Drug absorption, distribution, and elimination may shift with fluid redistribution and changes in renal and hepatic physiology, while emergency management of hemorrhage or recurrent thrombosis becomes much more constrained in orbit than in a hospital.
For that reason, even familiar agents may not behave in familiar ways. Anticoagulant selection in space would need to account not only for thrombotic risk, but also for the operational realities of prolonged travel, delayed evacuation, limited imaging, and finite onboard medication supply. Those are not abstract logistics; they are part of the treatment equation.
Existing risk scores are not designed for orbital physiology
Terrestrial VTE risk assessment tools were built around grounded populations with familiar exposures: surgery, cancer, immobility, pregnancy, trauma, and acute medical illness. Microgravity adds a different physiologic environment, and the review argues that existing tools likely need adaptation before they can be used confidently in astronauts. A scoring system that performs well on Earth may misclassify risk in orbit if it ignores the hemodynamic and hematologic changes unique to spaceflight.
This also affects how clinicians might think about prophylaxis. In routine practice, VTE prevention is often a balance between clot risk and bleeding risk. In microgravity, that balance becomes more uncertain because the baseline risk model itself is underdefined. The review therefore points toward a future in which risk stratification has to incorporate space-specific variables rather than simply transplant terrestrial assumptions into a new environment.
Research priorities now sit upstream of clinical protocols
The most immediate need is not a new drug, but direct evidence. The review calls for studies that can evaluate anticoagulant safety and efficacy in microgravity, refine risk assessment tools, and support evidence-based protocols for astronaut health. That agenda will probably require a combination of approaches: carefully designed analog studies on Earth, physiologic monitoring during space missions, and pharmacologic work that can characterize how anticoagulants behave under altered gravitational conditions.
A useful research program would need to answer several concrete questions. Which patients, if any, should receive prophylaxis before flight? Which agent offers the best compromise between thrombotic protection and bleeding risk? How should monitoring be done when standard laboratory infrastructure is unavailable or limited? And what thresholds should trigger treatment when symptoms suggest a clot but definitive imaging is not readily accessible?
The review does not provide a dosing algorithm, and it does not establish a preferred drug. It does, however, make the central uncertainty impossible to ignore: astronauts may face a physiologic setting in which clot biology changes, but medicine still lacks direct human evidence for how to prevent or treat VTE there. Until that gap closes, practice will remain anchored in extrapolation rather than space-specific data.